• Establishment Labs Holdings Inc. recently reported third-quarter 2025 results, posting revenue of US$53.78 million, up from US$40.23 million a year earlier, while net loss narrowed to US$11.15 million from US$16.68 million year-over-year.
• The company also raised its 2025 revenue guidance to exceed US$210 million, reflecting management’s confidence in continued sales growth and improving profitability.
• We will explore how management’s upward revision of annual revenue guidance impacts the company’s investment narrative and outlook.

Uncover the next big thing with financially sound penny stocks that balance risk and reward.

Establishment Labs Holdings Investment Narrative Recap

To be a shareholder in Establishment Labs Holdings, you need to believe in the company's ability to expand market share with innovative products and maintain sustained revenue growth, particularly in the U.S. Market optimism following the latest quarterly results and raised 2025 revenue guidance supports the short-term growth catalyst, but does not materially reduce the key risk of high operating expenses and the ongoing challenge of achieving consistent profitability.

Among recent developments, the publication of clinical data supporting the safety and effectiveness of the Mia Femtech procedure stands out. This adds credibility to management’s innovation agenda and aligns with the company’s growth catalysts in minimally invasive solutions, contributing to brand differentiation and potential increases in patient demand.

However, it is important to note that despite robust growth, investors should be aware of pressure on margins from rapid expense growth and...

Establishment Labs Holdings is projected to achieve $381.9 million in revenue and $27.5 million in earnings by 2028. This outlook assumes annual revenue growth of 29.1% and an earnings increase of $116 million from the current earnings of -$88.5 million.

Uncover how Establishment Labs Holdings' forecasts yield a $62.22 fair value, a 3% downside to its current price.

Exploring Other Perspectives

Three community fair value estimates for Establishment Labs range from US$40 to US$62.22 per share, showing wide variation in investor opinions. Many are focused on the potential impact of improved profitability milestones and expense control for the company’s path forward.

Explore 3 other fair value estimates on Establishment Labs Holdings - why the stock might be worth 37% less than the current price!

Build Your Own Establishment Labs Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Establishment Labs Holdings research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Establishment Labs Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Establishment Labs Holdings' overall financial health at a glance.

No Opportunity In Establishment Labs Holdings?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 36 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.